Uroxatral Related Published Studies
Well-designed clinical trials related to Uroxatral (Alfuzosin)
Medical expulsive therapy using alfuzosin for patient presenting with ureteral stone less than 10mm: a prospective randomized controlled trial. [2011.07]
The effects of tolterodine extended release and alfuzosin for the treatment of double-j stent-related symptoms. [2009.11]
Prospective randomized trial comparing efficacy of alfuzosin and tamsulosin in management of lower ureteral stones. [2009.04]
Efficacy and safety of combined oral therapy with tadalafil and alfuzosin: an integrated approach to the management of patients with lower urinary tract symptoms and erectile dysfunction. Preliminary report. [2009.02]
Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. [2009.01]
Alfuzosin and symptoms of chronic prostatitis-chronic pelvic pain syndrome. [2008.12.18]
Alfuzosin stone expulsion therapy for distal ureteral calculi: a double-blind, placebo controlled study. [2008.06]
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. [2007.01.09]
Rapid onset of action with alfuzosin 10 mg once daily in men with benign prostatic hyperplasia: a randomized, placebo-controlled trial. [2007]
Alfuzosin (10 mg) does not affect blood pressure in young healthy men. [2006.12]
Effects of acute treatment with tamsulosin versus alfuzosin on ejaculatory function in normal volunteers. [2006.10]
Hemodynamic interaction study between the alpha1-blocker alfuzosin and the phosphodiesterase-5 inhibitor tadalafil in middle-aged healthy male subjects. [2006.06]
Alfuzosin 10 mg once daily prevents overall clinical progression of benign prostatic hyperplasia but not acute urinary retention: results of a 2-year placebo-controlled study. [2006.04]
Comparison of the cardiovascular effects of tamsulosin oral controlled absorption system (OCAS) and alfuzosin prolonged release (XL). [2006.03]
Three months' treatment with the alpha1-blocker alfuzosin does not affect total or transition zone volume of the prostate. [2006]
Three months' treatment with the alpha(1)-blocker alfuzosin does not affect total or transition zone volume of the prostate. [2005.11.22]
A comparative study on the safety and efficacy of tamsulosin and alfuzosin in the management of symptomatic benign prostatic hyperplasia: a randomized controlled clinical trial. [2005.09]
Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia. [2005.05]
The vasodilatory effect of alfuzosin and tamsulosin in passive orthostasis: a randomised, double-blind, placebo-controlled study. [2005.03]
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. [2005.01]
Alfuzosin once daily facilitates return to voiding in patients in acute urinary retention. [2004.06]
Comparative efficacy of two alpha-adrenoreceptor antagonists, doxazosin and alfuzosin, in patients with lower urinary tract symptoms from benign prostatic enlargement. [2004.04]
First dose efficacy of alfuzosin once daily in men with symptomatic benign prostatic hyperplasia. [2003.11]
Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: a prospective, randomized, double-blind, placebo-controlled, pilot study. [2003.09]
Safety and efficacy of alfuzosin 10 mg once-daily in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a pooled analysis of three double-blind, placebo-controlled studies. [2003.08]
Randomised, placebo controlled, double blind study of alfuzosin SR in patients undergoing trial without catheter following acute urinary retention. [2002.10]
Alfuzosin, an alpha1-adrenoceptor antagonist for the treatment of benign prostatic hyperplasia: once daily versus 3 times daily dosing in healthy subjects. [2002.07]
Efficacy and safety of once-daily alfuzosin in the treatment of lower urinary tract symptoms and clinical benign prostatic hyperplasia: a randomized, placebo-controlled trial. [2001.12]
[Efficiency and tolerance of terazosine in ambulatory patients with benign prostatic hypertrophy: comparative randomized and double-blind trial versus alfuzosin. The MG Terazosine Group] [2000.04]
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study Group. [2000.03]
Sustained-release alfuzosin and trial without catheter after acute urinary retention: a prospective, placebo-controlled. [1999.10]
Sustained-release alfuzosin, finasteride and the combination of both in the treatment of benign prostatic hyperplasia. European ALFIN Study Group. [1998.09]
Comparison of tamsulosin with alfuzosin in the treatment of patients with lower urinary tract symptoms suggestive of bladder outlet obstruction (symptomatic benign prostatic hyperplasia). The European Tamsulosin Study Group. [1997.10]
Clinical uroselectivity: evidence from patients treated with slow-release alfuzosin for symptomatic benign prostatic obstruction. [1997.06]
Effects of short-term treatment with the alpha 1-blocker alfuzosin on urodynamic pressure/flow parameters in patients with benign prostatic hyperplasia. [1997]
Efficacy and safety of sustained-release alfuzosin 5 mg in patients with benign prostatic hyperplasia. ALGEBI Study Group. [1997]
Comparative effects of alfuzosin versus Serenoa repens in the treatment of symptomatic benign prostatic hyperplasia. [1995.01]
Belgian multicenter clinical study of alfuzosin, a selective alpha 1-blocker, in the treatment of benign prostatic hyperplasia. The Alfuzosin Belgian Group. [1994.12]
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 24-30 month survey. BPHALF Group. [1994.11]
Alfuzosin in the treatment of benign prostatic hyperplasia: effects on symptom scores, urinary flow rates and residual volume. A multicentre, double-blind, placebo-controlled trial. ALFECH Study Group. [1994]
Alpha-blocking treatment with alfuzosin in symptomatic benign prostatic hyperplasia: comparative study with prazosin. The PRAZALF Group. [1993.12]
Long-term treatment of benign prostatic hyperplasia with alfuzosin: a 12-18 month assessment. BPHALF Group. [1993.11]
Pharmacokinetics of alfuzosin after single oral administration to healthy volunteers, of three different doses. [1992.11]
Urinary flow rates in patients with benign prostatic hypertrophy following treatment with alfuzosin. DUALF Group. [1992.07]
Research in 'prostatitis syndromes': the use of alfuzosin (a new alpha 1-receptor-blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities. [1992]
Comparison of the new alpha 1-blocker alfuzosin with propranolol as first-line therapy in hypertension. [1991.07]
Alfuzosin for treatment of benign prostatic hypertrophy. The BPH-ALF Group. [1991.06.15]
Efficacy of alfuzosine (an alpha 1-adrenoreceptor blocking drug) in benign hyperplasia of the prostate. [1991]
Alfuzosin and the venous reflex response: studies in normal subjects. [1989.01]
Haemodynamic and pharmacokinetic evaluation of alfuzosin in man. A dose ranging study and comparison with prazosin. [1989]
[Efficacy of an alpha-blocker, alfuzosin, on urinary disorders in men with prostatic adenoma. Intermediate results of a European multicenter study] [1988]
Well-designed clinical trials possibly related to Uroxatral (Alfuzosin)
Role of alpha1-blockers in chronic prostatitis syndromes. [2008.03]
Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients. [2005.12]
Clinical assessment of drug-induced QT prolongation in association with heart rate changes. [2005.04]
Prostate size influences the outcome after presenting with acute urinary retention. [2004.09]
The efficacy and safety of a new once-a-day formulation of an alpha-blocker. [2001.03]
Tamsulosin 0.4 mg once daily: effect on sexual function in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. [1999.10]
Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms. [1998.07]
Prevention of urinary retention after general surgery: a controlled trial of carbachol/diazepam versus alfusozine. [1997.09]
Placebo effects in the pharmacological treatment of uncomplicated benign prostatic hyperplasia. The ALFECH Study Group. [1996.10]
Symptomatic outcome of transurethral prostatectomy, alpha-blockade and placebo in the treatment of benign prostatic hyperplasia. Evaluation of treatment with the Danish Prostatic Symptom Score (DAN-PSS-1) system. The ALFECH Study Group. [1996.04]
Validation of the self-administered Danish Prostatic Symptom Score (DAN-PSS-1) system for use in benign prostatic hyperplasia. [1995.10]
Alpha-1 blockade pharmacotherapy in primitive psychogenic premature ejaculation resistant to psychotherapy. [1995]
Other research related to Uroxatral (Alfuzosin)
Randomized crossover comparison of tamsulosin and alfuzosin in patients with urinary disturbances caused by benign prostatic hyperplasia. [2011.12]
The long-term effect of alfuzosin in patients with lower urinary tract symptoms suggestive of benign prostate hyperplasia: evaluation of voiding and storage function with respect to bladder outlet obstruction grade and contractility. [2011.05]
Influence of chemical permeation enhancers on transdermal permeation of alfuzosin: an investigation using response surface modeling. [2011.04]
Medical expulsive therapy using alfuzosin for patient presenting with ureteral
stone less than 10mm: a prospective randomized controlled trial. [2011]
Alfuzosin induced thrombocytopenia after treatment for benign prostatic hyperplasia. [2010.12]
Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. [2010.09]
[Alpha-1-blockers (alfuzosin) for obstructive salivary gland diseases]. [2010.06]
Tamsulosin versus Alfuzosin in the Treatment of Patients with Distal Ureteral Stones: Prospective, Randomized, Comparative Study. [2010.03]
An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. [2010.02]
Alfuzosin hydrochloride transdermal films: evaluation of physicochemical, in vitro human cadaver skin permeation and thermodynamic parameters. [2009.11]
The Effects of Tolterodine Extended Release and Alfuzosin for the Treatment of Double-J Stent-Related Symptoms. [2009.10.09]
A prospective randomized study comparing alfuzosin and tamsulosin in the management of patients suffering from acute urinary retention caused by benign prostatic hyperplasia. [2009.10]
[Use of alfuzosin for expulsion of stones in the distal third of ureter] [2009.10]
Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mg once daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. [2009.07]
Effects of alfuzosin and tamsulosin on sperm parameters in healthy men: results of a short-term, randomized, double-blind, placebo-controlled, crossover study. [2009.07]
Prospective Randomized Trial Comparing Efficacy of Alfuzosin and Tamsulosin in Management of Lower Ureteral Stones. [2009.02.02]
Effect of alfuzosin on female primary bladder neck obstruction. [2009.02]
Sexuality and the management of BPH with alfuzosin (SAMBA) trial. [2009.01]
Alfuzosin 10 mg once daily increases the chances of successful trial without catheter after acute urinary retention secondary to benign prostate hyperplasia. [2009]
Efficacy and Safety of Combined Oral Therapy with Tadalafil and Alfuzosin: An Integrated Approach to the Management of Patients with Lower Urinary Tract Symptoms and Erectile Dysfunction. Preliminary Report. [2008.12.02]
Alfuzosin attenuates erectile dysfunction in rats with partial bladder outlet obstruction. [2008.12]
Alfuzosin 10 mg once daily for treating benign prostatic hyperplasia: a 3-year experience in real-life practice. [2008.04]
Combination of alfuzosin and tadalafil exerts in vitro an additive relaxant effect on human corpus cavernosum. [2008.04]
Zero-order delivery of a highly soluble, low dose drug alfuzosin hydrochloride via gastro-retentive system. [2008.02.04]
Alfuzosin delays cardiac repolarization by a novel mechanism. [2008.02]
Medical therapy options for aging men with benign prostatic hyperplasia: focus on alfuzosin 10 mg once daily. [2008]
Effects of alfuzosin 10 mg once daily on sexual function in men treated for symptomatic benign prostatic hyperplasia. [2007.09]
Alfuzosin-induced acute liver injury. [2007.09]
Intraoperative floppy-iris syndrome associated with alpha1-adrenoreceptors: comparison of tamsulosin and alfuzosin. [2007.07]
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction. [2007.06]
Combination of Alfuzosin and Sildenafil is Superior to Monotherapy in Treating Lower Urinary Tract Symptoms and Erectile Dysfunction. [2007.01.16]
Comparison between tamsulosin and alfuzosin on the expulsion phase of ejaculation in rats. [2006.10]
Stuttering priapism after ingestion of alfuzosin. [2006.10]
Response to daily 10 mg alfuzosin predicts acute urinary retention and benign prostatic hyperplasia related surgery in men with lower urinary tract symptoms. [2006.09]
Alfuzosin (10mg) Does Not Affect Blood Pressure in Young Healthy Men. [2006.06.28]
The beneficial effect of alfuzosin 10 mg once daily in 'real-life' practice on lower urinary tract symptoms (LUTS), quality of life and sexual dysfunction in men with LUTS and painful ejaculation. [2006.06]
Alfuzosin: an alpha1-receptor blocker for the treatment of lower urinary tract symptoms associated with benign prostatic hyperplasia. [2006.04]
Long-term efficacy and safety of alfuzosin 10 mg once daily: a 2-year experience in 'real-life' practice. [2006.03]
|
